2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Sarcoma
1
Rhabdomyosarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma, Malignant
1
Medulloblastoma
1
Lethal Congenital Contracture Syndrome 2
1
Hemangiosarcoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Ipilimumab
17
tremelimumab
9
Nivolumab
9
durvalumab
8
pembrolizumab
6
Paclitaxel
5
Carboplatin
4
Capecitabine
4
Bevacizumab
4
lenvatinib
3
spartalizumab
2
balstilimab
2
Radiotherapy
2
Radiation
2
Pemetrexed
2
Oxaliplatin
2
Doxorubicin
2
Docetaxel
2
Cisplatin
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tilsotolimod
1
tebentafusp
1
relatlimab
1
poly ICLC
1
osimertinib
1
folfirinox
1
eribulin
1
envafolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Vascular Endothelial Growth Factor A
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled